Literature DB >> 7733883

Two site-directed mutations abrogate enzyme activity but have different effects on the conformation and cellular content of the N-acetylgalactosamine 4-sulphatase protein.

D A Brooks1, D A Robertson, C Bindloss, T Litjens, D S Anson, C Peters, C P Morris, J J Hopwood.   

Abstract

The sulphatase family of enzymes have regions of sequence similarity, but relatively little is known about either the structure-function relationships of sulphatases, or the role of highly conserved amino acids. The sequence of amino acids CTPSR at position 91-95 of 4-sulphatase has been shown to be highly conserved in all of the sequenced sulphatase enzymes. The cysteine at amino acid 91 of 4-sulphatase was selected for mutation analysis due to its potential role in either the active site, substrate-binding site or part of a key structural domain of 4-sulphatase and due to the absence of naturally occurring mutations in this residue in mucopolysaccharidosis type VI (MPS VI) patients. Two mutations, C91S and C91T, altering amino acid 91 of 4-sulphatase were generated and expressed in Chinese hamster ovary cells. Biochemical analysis of protein from a C91S cell line demonstrated no detectable 4-sulphatase enzyme activity but a relatively normal level of 4-sulphatase polypeptide (180% of the wild-type control protein level). Epitope detection, using a panel of ten monoclonal antibodies, demonstrated that the C91S polypeptide had a similar immunoreactivity to wild-type 4-sulphatase, suggesting that the C91S substitution does not induce a major structural change in the protein. Reduced catalytic activity associated with normal levels of 4-sulphatase protein have not been observed in any of the MPS VI patients tested and all show evidence of structural modification of 4-sulphatase protein with the same panel of antibodies [Brooks, McCourt, Gibson, Ashton, Shutter and Hopwood (1991) Am. J. Hum. Genet. 48, 710-719]. The loss of enzyme activity without a detectable protein conformation change suggests that Cys-91 may be a critical residue in the catalytic process. In contrast, analysis of protein from a C91T cell line revealed low levels of catalytically inactive 4-sulphatase polypeptide (0.37% of the wild-type control protein level) which had missing or masked epitopes, suggesting an altered protein structure or conformation. Subcellular fractionation studies of the C91T cell line demonstrated a high proportion of 4-sulphatase polypeptide content in organelles characteristic of microsomes. The aberrant intracellular localization and the reduced cellular content of 4-sulphatase polypeptide was consistent with the observed structural modification leading to retention and degradation of the protein within an early vacuolar compartment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733883      PMCID: PMC1136670          DOI: 10.1042/bj3070457

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  30 in total

1.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

2.  Diagnosis of Maroteaux-Lamy syndrome by the use of radiolabelled oligosaccharides as substrates for the determination of arylsulphatase B activity.

Authors:  J J Hopwood; H Elliott; V J Muller; G T Saccone
Journal:  Biochem J       Date:  1986-03-15       Impact factor: 3.857

3.  cDNA cloning, nucleotide sequence and expression of the gene for arylsulfatase in the sea urchin (Hemicentrotus pulcherrimus) embryo.

Authors:  H Sasaki; K Yamada; K Akasaka; H Kawasaki; K Suzuki; A Saito; M Sato; H Shimada
Journal:  Eur J Biochem       Date:  1988-10-15

4.  Human glucosamine-6-sulfatase cDNA reveals homology with steroid sulfatase.

Authors:  D A Robertson; C Freeman; P V Nelson; C P Morris; J J Hopwood
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

5.  Deficiency of chondroitin sulfate N-acetylgalactosamine 4-sulfate sulfatase in Maroteaux-Lamy syndrome.

Authors:  R Matalon; B Arbogast; A Dorfman
Journal:  Biochem Biophys Res Commun       Date:  1974-12-23       Impact factor: 3.575

6.  Cloning and expression of steroid sulfatase cDNA and the frequent occurrence of deletions in STS deficiency: implications for X-Y interchange.

Authors:  P H Yen; E Allen; B Marsh; T Mohandas; N Wang; R T Taggart; L J Shapiro
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

7.  Cloning and expression of human arylsulfatase A.

Authors:  C Stein; V Gieselmann; J Kreysing; B Schmidt; R Pohlmann; A Waheed; H E Meyer; J S O'Brien; K von Figura
Journal:  J Biol Chem       Date:  1989-01-15       Impact factor: 5.157

8.  Biosynthesis and maturation of arylsulfatase B in normal and mutant cultured human fibroblasts.

Authors:  F Steckel; A Hasilik; K von Figura
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

9.  Synthesis and stability of steroid sulfatase in fibroblasts from multiple sulfatase deficiency.

Authors:  J T Conary; A Hasilik; K von Figura
Journal:  Biol Chem Hoppe Seyler       Date:  1988-04

10.  Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B.

Authors:  G Arlt; D A Brooks; D Isbrandt; J J Hopwood; J Bielicki; T M Bradford; C A Bindloss-Petherbridge; K von Figura; C Peters
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

View more
  10 in total

1.  Processing of normal lysosomal and mutant N-acetylgalactosamine 4-sulphatase: BiP (immunoglobulin heavy-chain binding protein) may interact with critical protein contact sites.

Authors:  T M Bradford; M J Gething; R Davey; J J Hopwood; D A Brooks
Journal:  Biochem J       Date:  1999-07-01       Impact factor: 3.857

2.  Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients.

Authors:  T Litjens; D A Brooks; C Peters; G J Gibson; J J Hopwood
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

3.  Endocytosis and degradation of serglycin in liver sinusoidal endothelial cells.

Authors:  Berit Falkowska-Hansen; Inger Oynebråten; Lars Uhlin-Hansen; Bård Smedsrød
Journal:  Mol Cell Biochem       Date:  2006-05-30       Impact factor: 3.396

4.  Overexpression of inactive arylsulphatase mutants and in vitro activation by light-dependent oxidation with vanadate.

Authors:  Terri M Christianson; Chris M Starr; Todd C Zankel
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

5.  Non-clinical Safety and Efficacy of an AAV2/8 Vector Administered Intravenously for Treatment of Mucopolysaccharidosis Type VI.

Authors:  Rita Ferla; Marialuisa Alliegro; Jean-Brice Marteau; Margherita Dell'Anno; Edoardo Nusco; Severine Pouillot; Stefania Galimberti; Maria Grazia Valsecchi; Vincent Zuliani; Alberto Auricchio
Journal:  Mol Ther Methods Clin Dev       Date:  2017-07-24       Impact factor: 6.698

Review 6.  Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene.

Authors:  Rosella Tomanin; Litsa Karageorgos; Alessandra Zanetti; Moeenaldeen Al-Sayed; Mitch Bailey; Nicole Miller; Hitoshi Sakuraba; John J Hopwood
Journal:  Hum Mutat       Date:  2018-09-17       Impact factor: 4.878

7.  Generation of a novel disease model mouse for mucopolysaccharidosis type VI via c. 252T>C human ARSB mutation knock-in.

Authors:  Kosuke Hosoba
Journal:  Biochem Biophys Rep       Date:  2022-08-12

8.  Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease.

Authors:  Rita Ferla; Pamela Claudiani; Gabriella Cotugno; Paola Saccone; Elvira De Leonibus; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2014-04-11       Impact factor: 5.695

9.  Mutations in ARSB in MPS VI patients in India.

Authors:  Juby Mathew; Sujatha M Jagadeesh; Meenakshi Bhat; S Udhaya Kumar; Saravanamuthu Thiyagarajan; Sudha Srinivasan
Journal:  Mol Genet Metab Rep       Date:  2015-07-17

10.  Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.

Authors:  Marialuisa Alliegro; Rita Ferla; Edoardo Nusco; Chiara De Leonibus; Carmine Settembre; Alberto Auricchio
Journal:  Mol Ther       Date:  2016-09-23       Impact factor: 11.454

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.